Unum Therapeutics Inc (UMRX) Expected to Post Quarterly Sales of $3.10 Million

Equities analysts expect Unum Therapeutics Inc (NASDAQ:UMRX) to post $3.10 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Unum Therapeutics’ earnings. The highest sales estimate is $4.41 million and the lowest is $1.80 million. Unum Therapeutics reported sales of $1.67 million during the same quarter last year, which would suggest a positive year over year growth rate of 85.6%. The business is expected to report its next quarterly earnings results on Monday, August 12th.

According to Zacks, analysts expect that Unum Therapeutics will report full year sales of $13.82 million for the current fiscal year, with estimates ranging from $8.30 million to $17.60 million. For the next fiscal year, analysts anticipate that the company will post sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.08). The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.15 million. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Friday, April 26th. SunTrust Banks decreased their price target on shares of Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a research note on Friday, March 29th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Unum Therapeutics in a research note on Friday, March 29th. Finally, Cowen started coverage on shares of Unum Therapeutics in a research report on Tuesday, February 26th. They set a “market perform” rating on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $14.60.

Unum Therapeutics stock traded up $0.10 during mid-day trading on Monday, reaching $3.39. 4,955 shares of the company’s stock traded hands, compared to its average volume of 86,814. The company has a market cap of $102.40 million, a price-to-earnings ratio of -2.41 and a beta of 1.77. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.11. Unum Therapeutics has a 12-month low of $3.03 and a 12-month high of $17.66.

In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $4.12, for a total transaction of $47,318.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Several hedge funds and other institutional investors have recently bought and sold shares of UMRX. American International Group Inc. grew its holdings in shares of Unum Therapeutics by 432.8% in the fourth quarter. American International Group Inc. now owns 12,531 shares of the company’s stock worth $55,000 after purchasing an additional 10,179 shares during the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Unum Therapeutics in the first quarter worth about $61,000. Acadian Asset Management LLC bought a new position in shares of Unum Therapeutics in the first quarter worth about $61,000. Rhumbline Advisers bought a new position in shares of Unum Therapeutics in the first quarter worth about $85,000. Finally, State of Wisconsin Investment Board bought a new position in shares of Unum Therapeutics in the first quarter worth about $114,000. Hedge funds and other institutional investors own 47.27% of the company’s stock.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Featured Article: Yield Curve

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.